**Study Overview:** This study checks how well a medicine called Suzetrigine works to relieve pain from diabetic peripheral neuropathy (DPN). DPN is a nerve problem caused by diabetes, leading to pain, especially in the legs. The study also ensures the medicine is safe and can be tolerated by those who take it. **Eligibility Criteria:** Participants should weigh at least 45 kg and have a body mass index (BMI) between 18 and 40. They must have type 1 or type 2 diabetes, with an HbA1c level (a measure of blood sugar) of 9% or less. They should have had pain in both legs due to DPN for at least a year and a pain score between 4 and 9. Participants should not have missed more than 3 pain score recordings in the week before starting the study. Additionally, they should not have taken a medication called Journavx within 30 days before starting this study and shouldn't have other sensory issues not related to DPN. **Key Points:** - **Duration:** The study requires a commitment of time, but exact length and number of visits are not specified. - **Compensation:** Participants might receive compensation for their participation. - **Safety:** The study focuses on both the effectiveness and safety of the medication.

Consider your eligibility and willingness to participate based on these factors.